Navigation Links
Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone
Date:1/10/2011

OSAKA, Japan and DURHAM, N.C., Jan. 10, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and Zinfandel Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide licensing agreement regarding Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition. The companies will study pioglitazone in connection with the TOMM40 biomarker and Alzheimer's disease. Pioglitazone is the active ingredient currently marketed in Takeda's ACTOS® (pioglitazone HCl).

The TOMM40 biomarker, recently discovered by a team led by Allen Roses, M.D., Chief Executive Officer of Zinfandel, is being developed to identify individuals at high risk of developing Alzheimer's disease within the subsequent five years. Under this license agreement, Takeda and Zinfandel will attempt to prospectively validate the TOMM40 biomarker as a test of individual risk.

"There is intense interest within the medical community in identifying treatments to help delay progression or potentially prevent the onset of Alzheimer's disease, in an effort to reduce the burden of this disease," said Shigenori Ohkawa, Ph.D., Chief Scientific Officer, Takeda Pharmaceutical Company Limited. "We are energized by this partnership and the opportunity to develop an effective treatment for healthy at-risk older adults."

Under the terms of agreement, Zinfandel will receive an upfront payment of $9 million and subsequent payments of up to $78 million for development milestones from Takeda. Additional commercial milestones and royalties were also outlined in the agreement. Takeda will obtain an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay to identify high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.

"At Zinfandel, we have been exploring pharmacogene
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
2. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... less rosy indicators in overall global economic growth, Eugene ... optics and photonics , said in a featured talk ... on 5 December at the National Chung Hsing University ... which is being integrated into future energy supplies and ...
(Date:12/13/2014)... Charlotte, NC (PRWEB) December 13, 2014 ... nearly 3 million people between now and 2030." If ... will become the seventh most populous state in the ... Commerce is gathering at the Future of North Carolina ... We Ready? Do we have the necessary infrastructure in ...
(Date:12/13/2014)... -- Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company focused on ... G. H. Jordan , Ph.D., and David R. ... the total number of directors to eight, seven of ... , Chairman, President, and Chief Executive Officer of Vermillion, ... of Veronica and David to our board of directors.  ...
(Date:12/13/2014)... , Dec. 12, 2014  Vaccinex ... the discovery and development of therapeutic monoclonal ... today announced publication of a manuscript entitled ... inhibits remyelination in neurodegenerative disease" in the ... of Disease*.  The publication highlights an important ...
Breaking Biology Technology:Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2
... VRUS ) management will present at the Morgan ... 2008 to May 2,2008 at the Ritz-Carlton Key Biscayne ... provide an overview of the,company and participate in a ... 2008 at 3:40 PM (ET) in the Plaza,Ballroom., ...
... AANS/CNS Section on Tumors,and BrainLAB today announced the ... MD, from the People,s Republic of China, was,awarded ... Bone Marrow,Derived Mesenchymal Stem Cells in Brain Tumor ... a $50,000 stipend to conduct research in his,proposed ...
... 24 The Board of,Directors of Shire plc ... specialty,biopharmaceutical company, announces today that Michael Rosenblatt M.D.,will ... immediate effect., Dr Rosenblatt is the Dean ... was previously Professor of Medicine at Harvard,Medical School ...
Cached Biology Technology:Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th 2AANS/CNS and BrainLAB Announce Winner of 2008 International Research Fellowship 2AANS/CNS and BrainLAB Announce Winner of 2008 International Research Fellowship 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 2Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 3Dr Michael Rosenblatt Appointed Non-Executive Director at Shire 4
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Rice University,s Andrew Barron and his group, working with labs ... could block the means by which the deadly virus spreads ... Using computer simulations, researchers tested more than 100 ... other purposes to see if they could be used to ...
... 2009 A unique electrode developed for non-invasive use ... showing promising results in helping to interpret brain signals ... is also being studied as a means of delivering ... conventional disk-shaped electrode, the bulls-eye electrode is made up ...
... In research that could lead to new asthma drugs, ... Massachusetts, and the University of California, San Francisco have discovered ... in mice. They also demonstrated how a drug known to ... in mice. Their paper is published in the May 18-22 ...
Cached Biology News:International team tracks clues to HIV 2International team tracks clues to HIV 3Bull's-eye electrode helps interpret thoughts, deliver stimulus to aid paralyzed, epileptic patients 2Yale team identifies key to potential new treatment for allergy-induced asthma 2